Understand the source comparison
Best Peptides for Cardiac Health: Research Comparison
The table below summarizes the peptides demonstrating the strongest evidence base for cardiac protection, their primary mechanisms, and the clinical or preclinical endpoints they've shown to improve. SS-31 (Elamipretide) Mitochondrial membrane stabilization vi
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- The table below summarizes the peptides demonstrating the strongest evidence base for cardiac protection, their primary mechanisms, and the clinical or preclinical endpoints they've shown to improve.
- SS-31 (Elamipretide)
- Mitochondrial membrane stabilization via cardiolipin binding
- Phase 2 RCT
- Improved LVEDV, reduced NT-proBNP in heart failure (JACC 2020)
- Strongest mitochondrial-targeted peptide with human trial data. Binds specifically to inner mitochondrial membrane
- Thymosin Beta-4
- Angiogenesis via VEGF upregulation and actin modulation
- Phase 1 clinical trial
- Reduced infarct size, improved regional wall motion post-MI (The Lancet)
- Promotes endothelial migration and progenitor cell differentiation. Effective within 24 hours of acute MI
- MOTS-C
- AMPK activation, metabolic flexibility enhancement
- Preclinical (rodent models)
- 38% infarct size reduction, preserved EF post-coronary ligation (Nature Med)
- Mitochondrial-derived peptide with nuclear signaling. Requires daily dosing due to 4–6 hour half-life
- BPC-157
- NO stabilization, endothelial repair
- Restored blood flow to ischemic tissue within 72 hours (J Physiol Pharmacol)
- Potent angiogenic activity. Lacks human cardiac RCT data but extensive vascular repair evidence
- ARA-290
- Tissue-protective receptor activation, anti-inflammatory
- Phase 2 RCT (non-cardiac)
- Reduced inflammatory biomarkers, improved neuropathy scores
- Selective for innate repair receptor. Avoids EPO thrombotic risk while preserving cytoprotection
- Thymosin Alpha-1
- T-cell modulation, reduced cytokine release
- Preclinical (rodent MI models)
- 47% reduction in IL-6, preserved LV function (Eur J Pharmacol)
- Immune-modulating peptide effective post-ischemia-reperfusion. Dampens maladaptive inflammation